Roche Holding AG to Discuss Gazyva in Lupus Nephritis Presented at ASN/ASR 2019 Transcript
Ladies and gentlemen, welcome to the Roche live audio webcast on Gazyva in lupus nephritis presented at ASN/ACR 2019 conference call. I am Andre, the Chorus Call operator. (Operator Instructions) The conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast.
At this time, it's my pleasure to hand over to Karl Mahler, Head of Investor Relations. Please go ahead, sir.
Yes, thank you, Andre. Also, a warm welcome from my side to everybody joining us for this Roche audio webcast to discuss the Gazyva Phase II data in lupus nephritis. Actually, we have presented these data over the past 2 weeks at 2 different congresses, at ASN as well as at ACR, the American Society of Nephrology. And I am pleased that we have with us today, Mark Eisner, the Global Head of Product Development, Immunology, Infectious Diseases and Ophthalmology, who will start this call by giving us a short overview on the Roche -- of Roche in immunology. And this will be followed by Larry
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
